SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation
therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment
before pembrolizumab in patients with metastatic triple negative breast cancer (TNBC) and
metastatic non-small cell lung cancer (NSCLC). In situ oncolytic virus therapy will consist
of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus
valacyclovir therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute